Next-Generation EpiScreen® Immunogenicity Assay

The promise of protein therapeutics is often hampered by unforeseen immune reactions. Assessing a drug candidate's immunogenic potential early in development is critical for success. Traditional methods, while sensitive, come with limitations. This study presents a novel flow cytometry-based assay that offers exceptional sensitivity without compromising on traditional methods.

This innovative platform goes beyond simply detecting immune response; it unveils the activation status of responding immune cells. This data-rich approach provides a deeper understanding of immunogenicity risk, particularly for cutting-edge therapies like gene therapy. By observing cellular activation alongside proliferation, researchers can make informed decisions about which drug candidates hold the greatest promise for successful clinical trials.

This new method empowers researchers to navigate the complexities of protein therapeutic development, ultimately leading to safer and more effective treatments for patients.